1380228-53-4

Basic information

• Product Name: N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide
• Synonyms: N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide
• CAS NO: 1380228-53-4
• Molecular Weight: 479.47
• Mol File: 1380228-53-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide(1380228-53-4)
• EPA Substance Registry System: N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide(1380228-53-4)

Safety Data

• Hazardous Substances Data: 1380228-53-4(Hazardous Substances Data)

Upstream product

• 5509-65-9 2,6-difluoroaniline 
• 946826-47-7 N-(3-amino-2,6-difluorophenyl)acetamide 
• 7306-68-5 6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 1380229-14-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)benzenesulfonamide 
• 535170-20-8 tert-butyl (3-amino-2,6-difluorophenyl)carbamate 
• 535170-17-3 tert-butyl (2,6-difluoro-3-nitrophenyl)carbamate 
• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 
• 1380228-73-8 2,6-difluoro-N₁-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-yl)benzene-1,3-diamine 
• 1380228-71-6 benzyl 2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl carbamate 
• 1380228-68-1 benzyl tert-butyl (2,4-difluoro-1,3-phenylene)dicarbamate 
• 87-42-3 6-chloropurine 
• 260552-98-5 2,6-difluoro-3-nitrobenzoic acid chloride 
• 1093101-52-0 6-(2-fluoropyridin-3-yl)-9-(tetrahydro-2-hydro-pyran-2-yl)-9H-purine 
• 385-00-2 2,6-difluorobenzoic acid 

Relevant articles and documents

Protein kinase inhibitor and its composition and use thereof

The invention relates to compounds as shown in the general formula (I), pharmaceutical compositions containing the compounds, a method for treating diseases and disease symptoms related to abnormal activity of protein kinase by using the compounds, and medicinal use of the compounds.

Discovery of a highly specific and potent pan-RAF inhibitor

We describe the structure-based design and synthesis of N-(2,6-difluorophenyl)-3-(9H-purin-6-yl)pyridine-2-amine derivatives as a selective pan-RAF kinase inhibitor. The synthesized compounds showed highly potent and specific inhibition of the BRAFV600E mutant cell line. Among them, N-(3-((3-(9H-purin-6-yl) pyridine-2-yl)amino)-2,4-difluorophenyl)furan-3-sulfonamide (4b) exhibited the most potent inhibitory activities against protein kinase enzymes BRAFV600E, BRAFWT, and CRAF (IC50 of 2, 2, and 1 nM, respectively) and a mutant cell line bearing a BRAFV600E mutation, A375P (GI50 of 7 nM).

NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT

A novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient are provided. The purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the present invention effectively regulates the activity of B-Raf kinase, and thus may be useful for preventing or treating cancers induced by the over-activation of Raf kinase, especially various melanoma, colorectal cancer, prostate cancer, thyroid cancer, ovarian cancer and the like.